Medicinova (MNOV) to discontinue development of SARS-CoV-2 vaccine for COVID-19
- Wall St slips as higher yields offset upbeat corporate earnings
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Boeing reports first revenue drop in 7 quarters as deliveries decline
- Oil prices fall as U.S. business activity cools, concerns over Middle East ease
- Yen on the brink, but Tesla pulls back
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Hasbro (HAS) brand strength sees earnings top expectations
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
MediciNova Announces Update on SARS-CoV-2 Vaccine for COVID-19
March 3, 2021 6:30 AM ESTLA JOLLA, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an update on the development of a SARS-CoV-2 vaccine for COVID-19. MediciNova has conducted a careful review of its numerous development programs to determine the best allocation of resources going forward considering the stage of development, expected costs of completing clinical development, and the competitive landscape. Given the COVID-19 vaccines currently in use and other vaccines in advanced stages of... More